PTC Therapeutics Inc (PTCT)
33.01
-0.61
(-1.81%)
USD |
NASDAQ |
May 03, 16:00
32.98
-0.03
(-0.09%)
Pre-Market: 20:00
PTC Therapeutics Revenue (Quarterly): 210.12M for March 31, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 210.12M |
| December 31, 2023 | 307.06M |
| September 30, 2023 | 196.58M |
| June 30, 2023 | 213.81M |
| March 31, 2023 | 220.38M |
| December 31, 2022 | 167.41M |
| September 30, 2022 | 217.13M |
| June 30, 2022 | 165.53M |
| March 31, 2022 | 148.74M |
| December 31, 2021 | 165.23M |
| September 30, 2021 | 138.74M |
| June 30, 2021 | 116.68M |
| March 31, 2021 | 117.94M |
| December 31, 2020 | 118.86M |
| September 30, 2020 | 118.40M |
| June 30, 2020 | 75.24M |
| March 31, 2020 | 68.26M |
| December 31, 2019 | 96.46M |
| September 30, 2019 | 71.42M |
| June 30, 2019 | 85.52M |
| March 31, 2019 | 53.58M |
| December 31, 2018 | 86.34M |
| September 30, 2018 | 53.59M |
| June 30, 2018 | 68.74M |
| March 31, 2018 | 56.06M |
| Date | Value |
|---|---|
| December 31, 2017 | 78.03M |
| September 30, 2017 | 41.85M |
| June 30, 2017 | 47.96M |
| March 31, 2017 | 26.55M |
| December 31, 2016 | 25.19M |
| September 30, 2016 | 22.99M |
| June 30, 2016 | 15.63M |
| March 31, 2016 | 18.90M |
| December 31, 2015 | 12.73M |
| September 30, 2015 | 9.776M |
| June 30, 2015 | 6.774M |
| March 31, 2015 | 7.482M |
| December 31, 2014 | 13.88M |
| September 30, 2014 | 0.797M |
| June 30, 2014 | 1.418M |
| March 31, 2014 | 9.147M |
| December 31, 2013 | 7.301M |
| September 30, 2013 | 15.46M |
| June 30, 2013 | 5.868M |
| March 31, 2013 | 6.072M |
| December 31, 2012 | 5.918M |
| September 30, 2012 | 6.043M |
| June 30, 2012 | 6.064M |
| March 31, 2012 | 10.75M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
68.26M
Minimum
Mar 2020
307.06M
Maximum
Dec 2023
150.97M
Average
143.74M
Median
Revenue (Quarterly) Benchmarks
| Sarepta Therapeutics Inc | 413.46M |
| Pfizer Inc | 14.88B |
| Catalyst Pharmaceuticals Inc | 110.57M |
| Geron Corp | 0.304M |
| Perspective Therapeutics Inc | -5.239M |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -91.58M |
| Total Expenses (Quarterly) | 255.67M |
| EPS Diluted (Quarterly) | -1.20 |
| Enterprise Value | 1.931B |
| Gross Profit Margin (Quarterly) | 92.98% |
| Profit Margin (Quarterly) | -43.58% |
| Earnings Yield | -23.27% |
| Normalized Earnings Yield | -14.83 |